The approval marks a significant milestone as the first GLP-1 therapy approved for MASH, expanding treatment options for patients and providers. "We congratulate Novo Nordisk on this landmark ...

Copenhagen-listed shares in pharmaceuticals giant Novo Nordisk rose nearly 4% on Monday morning, after the company announced ...

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...